Is the treatment effect of Pemigatinib good

Pemigatinib is an effective treatment for advanced or metastatic cholangiocarcinoma caused by FGFR2 fusion or rearrangement.

Is the treatment effect of Pemigatinib good

In the FIGHT-202 clinical trial, Pemigatinib showed significant efficacy in patients with cholangiocarcinoma with FGFR2 gene fusion or rearrangement. Results from a clinical trial of 146 patients showed lesion shrinkage of more than 30%, median overall survival (mOS) of 17.5 months, and a defined response rate of 37%. Among them, patients who are clinically identified as partially relied on can achieve a median overall survival (mOS) of 30.1 months, demonstrating the advantage of Pemigatinib in prolonging patient survival.

Is the safety of Pemigatinib good?

Pemigatinib has shown excellent efficacy, but patients also need to be aware of possible side effects during use.

Based on the experience of clinical trials and clinical practice, common side effects of Pemigatinib include diarrhea, fatigue, nail toxicity, hair loss (alopecia areata), hypophosphatemia and hyperphosphatemia, abdominal pain, etc. In addition, adverse effects such as dry eyes, distorted taste, dry skin, joint pain, dry mouth, nausea, pain or inflammation in the mouth, back pain, decreased appetite, constipation, vomiting, and ocular toxicity may occur. 

When using Pemigatinib, patients need to follow the doctor's instructions to standardize the medication, pay close attention to the body's reaction, and seek medical attention in time if there is serious discomfort.

The therapeutic effect of Pemigatinib in clinical practice

The therapeutic effect of Pemigatinib has been verified through a number of clinical trials, and its specific clinical manifestations can be summarized as follows.

1. Overall response rate (ORR)

In the FIGHT-202 clinical trial, the overall response rate of Pemigatinib monotherapy was 36 percent, including 2.8 percent complete response and 33 percent partial response. This means that more than one-third of patients experience significant tumor volume reduction after treatment with Pemigatinib.

2. Disease Control Rate (DCR)

The clinical trial also showed a disease control rate of 82%, indicating that Pemigatinib is effective in controlling tumor growth and spread in most cases.

【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.